Interim Reports
Interim Report 2010
Highlights
- Board restructure and appointment of new Chairman, Tom Bannatyne
- Evaluation agreement with major consumer healthcare company for synergistic pair of antimicrobials with patent application pending
- Completion of Phase II clinical study of acneic skin has led to discussions with major healthcare companies
- Strong patent portfolio with 24 core patents/applications. 11 patents have been granted in the UK
- Finalising plans for proposed equity fund raising to progress commercial opportunities.
Interim Report 2009
Highlights
- Initiated a further Phase II proof-of-concept clinical study.
- Our Exclusivity and Evaluation agreement with a major consumer healthcare company has been renewed for a further 12 months.
- Additional placing in August 2008 raising funding of £1.48 million (net of expenses).
- Strong patent portfolio with 17 core patents/applications. 5 patents have been granted in the UK.
Interim Report 2008
Highlights
- Positive results from our first Phase I study.
- First commercial exclusive evaluation agreement with a major consumer healthcare company.
- Strengthening prospects for further licensing and joint development agreements with other healthcare and dermatological companies.
- Expanding library of compounds and combinations of compounds.
- Growing intellectual property portfolio with three granted patents and 12 patent applications.
Interim Report 2007
Highlights
- MHRA approval to conduct first Phase I clinical trial.
- Clinical Research Organisation appointed.
- Formulations of other compounds initiated for further human use studies.
- Compound library now contains over 1,000 compounds for screening.
- Growing patent portfolio which is continually being evaluated.
- Cash balance at 31 January 2007 of £2.5 million (31 January 2006: £323,000).
- Tight overhead cost control.
- Development programme costs in line with budget.
Recent News
23/08/2010 07:00
AGREEMENT WITH GLOBAL CONSUMER PRODUCTS COMPANY
Syntopix signs an exclusive agreement with a world leading health and personal care brands company.
22/06/2010 07:00
Syntopix welcomes a new board member with Mike Townend joining as Non-executive Director
22/04/2009 13:13
03/02/2010 07:00
Syntopix announces a Directorate change with Tom Bannatyne joining as Chairman.
12/11/2009 07:00
Syntopix announces positive results for its lead dermatological compound SYN0126
